S&P 500   3,119.40 (-0.08%)
DOW   27,969.61 (-0.24%)
QQQ   203.23 (+0.08%)
BABA   185.52 (+0.49%)
GE   11.34 (-0.87%)
ACB   2.30 (+0.88%)
F   8.94 (-0.11%)
PRI   131.08 (-0.02%)
BAC   32.95 (-0.03%)
S&P 500   3,119.40 (-0.08%)
DOW   27,969.61 (-0.24%)
QQQ   203.23 (+0.08%)
BABA   185.52 (+0.49%)
GE   11.34 (-0.87%)
ACB   2.30 (+0.88%)
F   8.94 (-0.11%)
PRI   131.08 (-0.02%)
BAC   32.95 (-0.03%)
S&P 500   3,119.40 (-0.08%)
DOW   27,969.61 (-0.24%)
QQQ   203.23 (+0.08%)
BABA   185.52 (+0.49%)
GE   11.34 (-0.87%)
ACB   2.30 (+0.88%)
F   8.94 (-0.11%)
PRI   131.08 (-0.02%)
BAC   32.95 (-0.03%)
S&P 500   3,119.40 (-0.08%)
DOW   27,969.61 (-0.24%)
QQQ   203.23 (+0.08%)
BABA   185.52 (+0.49%)
GE   11.34 (-0.87%)
ACB   2.30 (+0.88%)
F   8.94 (-0.11%)
PRI   131.08 (-0.02%)
BAC   32.95 (-0.03%)
Log in

Arrowhead Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:ARWR)

$50.67
+2.50 (+5.19 %)
(As of 11/19/2019 10:31 AM ET)
Today's Range
$49.02
Now: $50.67
$50.78
50-Day Range
$26.96
MA: $37.43
$48.30
52-Week Range
$10.41
Now: $50.67
$49.78
Volume21,911 shs
Average Volume1.51 million shs
Market Capitalization$4.80 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.14 million
Book Value$1.08 per share

Profitability

Net Income$-54,450,000.00

Miscellaneous

Employees116
Market Cap$4.80 billion
Next Earnings Date11/25/2019 (Confirmed)
OptionableOptionable

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.62 million. Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 25th 2019. View Earnings Estimates for Arrowhead Pharmaceuticals.

How can I listen to Arrowhead Pharmaceuticals' earnings call?

Arrowhead Pharmaceuticals will be holding an earnings conference call on Monday, November 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for ARWR?

5 brokerages have issued twelve-month price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $39.00 to $59.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $49.40 in the next twelve months. This suggests that the stock has a possible downside of 2.5%. View Analyst Price Targets for Arrowhead Pharmaceuticals.

What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

Media stories about ARWR stock have trended somewhat positive on Tuesday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Arrowhead Pharmaceuticals.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a decrease in short interest in October. As of October 15th, there was short interest totalling 14,810,000 shares, a decrease of 7.5% from the September 15th total of 16,010,000 shares. Based on an average daily trading volume, of 1,400,000 shares, the short-interest ratio is presently 10.6 days. Approximately 16.8% of the company's shares are sold short. View Arrowhead Pharmaceuticals' Current Options Chain.

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA), Sasol (SSL), salesforce.com (CRM), Walt Disney (DIS), Sarepta Therapeutics (SRPT) and Bank of America (BAC).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 65)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 55)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.30%), Rhumbline Advisers (0.30%), First Trust Advisors LP (0.15%), New York State Teachers Retirement System (0.14%), Bailard Inc. (0.11%) and Comerica Bank (0.09%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, First Trust Advisors LP, Bailard Inc., Mackay Shields LLC, Meeder Asset Management Inc., Vanguard Capital Wealth Advisors, Creative Planning and First Quadrant L P CA. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was purchased by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, State of New Jersey Common Pension Fund D, Moody Lynn & Lieberson LLC, SG Americas Securities LLC, State of Alaska Department of Revenue, California Public Employees Retirement System, Texas Permanent School Fund and Arlington Capital Management Inc.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $50.67.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $4.80 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  402 (Vote Outperform)
Underperform Votes:  341 (Vote Underperform)
Total Votes:  743
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel